The information set forth and the opinions, assumptions and projections contained in this document have been provided in good faith, based on a reasonable belief in its accuracy. However, no assurance can be given that the opinions and assumptions are correct or that any of the projections, expectations or transactions contemplated herein will be attained. All forward looking statements herein involve known and unknown risks, uncertainties and other factors that may cause the actual results and performance of the company to be materially different.

©2018 by Everads Therapy. Proudly created with Wix.com



Everads Therapy’s platform delivery system consists of a blunt injector for applying its unique access method to targeting the back of the eye:


Targeted delivery of the therapeutic agent to choroid and retina, with excellent distribution
Potential for longer lasting effect of drug
Applicable for small and large molecules, larger volumes, gene and cell therapy


Posterior segment reach does not interfere with the visual axis and does not involve the
anterior chamber, minimizing potential side effects (IOP, cataract)

Minimally invasive

Designed as an office-based procedure, simple and easy to use

Demonstrated by extensive preclinical studies




This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 882359